Plus Therapeutics Gets FDA ODD For Rhenium (186Re) Obisbemeda; Stock Surges In Pre-market

(RTTNews) - Shares of Plus Therapeutics, Inc. (PSTV) were surging around 80 percent in the pre-market activity on the Nasdaq after the company announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to Rhenium (186Re) Obisbemeda for the treatment of leptomeningeal metastases (LM) in patients with lung cancer.

LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid (CSF) and leptomeninges surrounding the brain and spinal cord.

Rhenium (186Re) obisbemeda is a novel injectable radiotherapy specifically formulated to deliver highly targeted high dose radiation in central nervous system or CNS tumors in a safe, effective and convenient manner. It has the potential to reduce risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose.

The clinical-stage pharmaceutical company, which develops, targeted radiotherapeutics with advanced platform technologies for CNS cancers, noted that the milestone follows the recent completion of the ReSPECT-LM Phase 1 single-dose trial, which established the recommended Phase 2 dose (RP2D).

Plus Therapeutics is now advancing a Phase 2 single-dose expansion trial and a Phase 1 multiple-dose trial while actively engaging the FDA to define the optimal pivotal trial strategy.

The FDA grants ODD status to an investigational drug or biologic intended to prevent, diagnose, or treat a rare disease or condition affecting fewer than 200,000 people in the United States.

With ODD, drug developers will get certain benefits, including seven potential years of market exclusivity, tax credits for qualified clinical trials, and exemptions from significant regulatory fees, including the Prescription Drug User Fee Act (PDUFA) charge of $4.3 million in 2025 and the Pediatric Research Equity Act (PREA) requirements.

For More Such Health News, visit rttnews.com